A novel immune-related gene signature predicting survival in sarcoma patients.

Mol Ther Oncolytics · 2022 · PMC8718575 · PMID 35024438

Europe PMC DOI

hedged sentence

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

highly significantp < 0.0001actually significant

The high-risk group had a highly significant decreased OS compared with the low-risk group (p < 0.0001, hazard ratio [HR] = 8.98, 95% CI: 5.06–15.94; Figure 4 C).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.